Mike specialises in the pharmaceutical field and has considerable experience in due diligence evaluations, licence negotiations, patent term extension, regulatory data exclusivity and patent listings with regulatory authorities. His role focuses on the drafting and worldwide prosecution and defence of new chemical entity, formulation, drug delivery, salts, crystalline forms, co-crystals, and process and use patents. He also has considerable experience in oppositions and appeals at the European Patent Office.
Mike started his patent career with a major speciality chemical company, where he worked on a range of technologies including dyestuffs, ink formulations, electrophotography and industrial biocides.
Prior to joining HGF, Mike worked in-house for more than ten years for a global pharmaceutical company. There he managed patent matters across all stages of pharmaceutical research and development, including drafting, litigation, opinions, freedom to operate evaluations and providing strategic IP advice to both technical and management teams within the business. Mike coordinated global patent litigation strategy for a major product which involved briefing technical teams to prepare evidence, advising senior stakeholders and coordinating preliminary injunction, infringement and revocation actions.
Mike also provided support to business development activities and worked on numerous due diligence evaluations and negotiations, including early stage discovery agreements, peer-to-peer collaborations, late stage product acquisitions and in-licence agreements. Mike is able to draw on his broad experiences to provide clients with commercially focused and pragmatic patent and business development strategies. He can therefore act as a quasi-in-house patent counsel for clients, working with both scientists and management to guide commercial and technical developments - thereby maximising the value which IP gives to the business. Alongside these skills, Mike has the expertise required to implement the patent strategy in the day-to-day conduct of clients' patent activities.